We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
- Authors
Vazquez, Juan Carlos; Antolin, Silvia; Ruiz-Borrego, Manuel; Servitja, Sonia; Alba, Emilio; Barnadas, Agusti; Lluch, Ana; Martin, Miguel; Rodriguez-Lescure, Alvaro; Sola, Ivan; Bonfill, Xavier; Urrutia, Gerard; Sanchez-Rovira, Pedro
- Abstract
Background: We aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. Methods: We carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival. Results: We identified eleven randomized clinical trials (2836 patients). When comparing paclitaxel plus dual treatment versus paclitaxel plus trastuzumab or lapatinib, dual treatment was associated with a higher probability of achieving a pathological complete response (OR 2.88, 95% CI 2.02–4.10). Addition of a taxane to an anthracycline plus cyclophosphamide and fluorouracil, plus lapatinib or trastuzumab, showed that the dual treatment was better than lapatinib alone (OR 2.47, 95% CI 1.41–4.34), or trastuzumab alone (OR 1.89, 95% CI 1.13–3.16). Dual treatment may result in an increase in survival outcomes and tumour clinical response, although such benefits are not consistent for all the combinations studied. Conclusions: The use of dual blockade with combinations of trastuzumab and pertuzumab can be recommended for the neoadjuvant treatment of women with HER2-positive breast cancer. PROSPERO Registration number: CRD42018110273.
- Publication
Clinical & Translational Oncology, 2023, Vol 25, Issue 4, p941
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-022-02998-2